ClinicalTrials.gg
CompletedNCT01242072Updated Sep 29, 2026

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

A Phase 1 interventional study of palifosfamide-tris in Malignancy, Cancer and Non Small Cell Lung Cancer, sponsored by Alaunos Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Alaunos Therapeutics · Phase 1, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.

02

Conditions studied

  • Malignancy
  • Cancer
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Testicular Cancer
  • Thymoma
  • Ovarian Cancer
  • Osteosarcoma

Keywords

  • malignancy
  • etoposide and carboplatin
  • non small cell lung cancer
  • small cell lung cancer
  • testicular cancer
  • thymoma
  • ovarian cancer
  • osteosarcoma
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 22 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Alaunos Therapeutics is the lead sponsor of 37 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or greater
  • scheduled to receive etoposide and carboplatin therapy
  • (ECOG) performance of 0 or 1
  • Adequate bone marrow, liver, renal function and coagulation status
  • Agree to use through 28 days of last treatment dose
  • Pregnancy test for women of
  • No available standard therapy

Exclusion criteria

Exclusion Criteria:

  • Allergy to the the study treatment drugs
  • Unstable current medical condition
  • Presence or history of injury to the urinary tract
  • Active infection
  • Major surgery within 4 weeks prior to treatment
  • Minor surgery within 2 weeks prior to treatment
  • Current acute therapy or taper
  • Currently pregnant or nursing
  • Substance abuse or condition that may interfere with participation
  • Received other drugs within 30 days
  • Within 4 weeks of their last chemotherapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    PaCE

    Palifosfamide, Carboplatin and Etoposide

    Drug: palifosfamide-tris

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the safety profile

    Adverse events, vital signs, physical examination, laboratory data and concomitant medications

    Time frame: 21 Days

Secondary outcomes

  1. Determine the maximum tolerated dose

    Each dose level cohort will be 3 subjects. After 3 subjects have received a regimen, there will be a minimum observation period of 1 full cycle (21 days) for each of the 3 subjects before enrollment of the group of subjects at the next dose level.

    Time frame: Up to 21 days

  2. Assess early signs of efficacy

    To assess early signs of efficacy using this investigational combination in this patient population

    Time frame: duration of study

07

Study locations

4 sites
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Horizon Oncology Research
    Lafayette, Indiana 47905, United States
  • Medical Consultants, PC
    Muncie, Indiana 47303, United States
  • Washington University
    St Louis, Missouri 63110, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in Jul 2012, 19 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 19 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Nov 2010 → Dec 2010, primary completion Dec 2012 → Jul 2012 and completion Dec 2012 → Jul 2012.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2010
First posted
Nov 16, 2010
StartActual
Dec 2010was Nov 2010
Primary completionActual
Jul 16, 2012was Dec 2012
CompletionActual
Jul 16, 2012was Dec 2012
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Sep 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Washington University · St Louis, United States
Show 1 removed
  • Washington University · St. Louis, United States
Sep 29, 2026
Start date
Nov 2010→Dec 2010 (actual)
Sep 29, 2026
Primary completion
Dec 2012→Jul 16, 2012 (actual)
Sep 29, 2026
Study completion
Dec 2012→Jul 16, 2012 (actual)
Sep 29, 2026
Enrollment
12 (estimated)→22 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Washington University · St Louis, United States
    Show 1 removed
    • Washington University · St. Louis, United States
    Start date Nov 2010→Dec 2010 (now actual)
    Primary completion Dec 2012→Jul 16, 2012 (now actual)
    Study completion Dec 2012→Jul 16, 2012 (now actual)
    Enrollment 12 (estimated)→22 (actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01242072
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Dec 2010
Primary completion
Jul 16, 2012
Completion
Jul 16, 2012
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isophosphamide mustard

Start the discussion